Nazi imagery and symbolism are increasingly moving from the darkest corners of American society to its political mainstream, ...

In this episode of "Uncanny Valley," we discuss the economics and environmental impacts of energy-hungry data centers and ...

To lead in the agentic era, executives must champion synthetic data as a foundation for innovation, while pairing it with ...

David AI Labs Inc. a startup selling audio data sets to help train artificial intelligence models, has raised $50 million from investors in a new round of funding — signaling a growing market for ...

When it comes to deal curation, data is a differentiator. Index Exchange knows this – hence why the SSP launched what it calls its Data Vendor Ecosystem on Tuesday. The idea is for the product to ...

Governor Gavin Newsom recently signed SB 446 into law, introducing significant changes to California’s data breach notification requirements. The bill establishes deadlines for notifying consumers and ...

Nvidia makes the chips that support artificial intelligence, making it something of a picks-and-shovels play on AI. AI needs to "live" somewhere, which favors real estate investment trusts. AI needs ...

CAMPBELL COUNTY, Va. (WSET) — The Campbell County Board of Supervisors is set to vote on a plan Tuesday that could bring three data centers to Concord, but the project has sparked a lot of debate in ...

The industry believes AI will work its way into every corner of our lives, and so needs to build sufficient capacity to address that anticipated demand. But the hardware used to make AI work is so ...

PEN America's report found 6,870 instances of book bans in 2024 and 2025. Books bans in public schools have become a "new normal" in the U.S., escalating since 2021, according to one advocacy group.

Oct 1 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab, Takeda Pharmaceuticals (4502.T), opens new tab and Astex Pharmaceuticals are coming together to share proprietary data for training an ...

Opus Genetics has shared data on its gene therapy in children with an ultrarare eye disease, setting the biotech up to talk to the FDA about the next steps for the program. North Carolina-based Opus ...